12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Additional Phase III data

Additional data from the double-blind, international Phase III AVAglio trial in 921 patients with newly diagnosed glioblastoma showed that Avastin plus temozolomide and radiation led to a median PFS, a co-primary endpoint, of 10.6 months vs. 6.2 months for placebo plus temozolomide and radiation (HR=0.64, p<0.0001). However, interim data from the trial showed that Avastin plus temozolomide and radiation did not significantly improve OS, a co-primary endpoint, vs. placebo plus temozolomide and radiation (HR=0.89, p=0.2135). Final OS data are expected in 2013. On secondary endpoints, the...

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >